<?xml version="1.0" encoding="UTF-8"?><?xml-stylesheet type="text/xsl" href="https://www.accessdata.fda.gov/spl/stylesheet/spl.xsl"?>
<document xmlns="urn:hl7-org:v3" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:schemaLocation="urn:hl7-org:v3 https://www.accessdata.fda.gov/spl/schema/spl.xsd">
   <id root="a5dc0ad6-1b71-45f9-b00b-cac2f5e2a26b"/>
   <code code="34391-3" codeSystem="2.16.840.1.113883.6.1" displayName="HUMAN PRESCRIPTION DRUG LABEL"/>
   <title>These highlights do not include all the information needed to use Metronidazole Gel, 1% safely and effectively. See full prescribing information for Metronidazole Gel, 1%<br/>Metronidazole Gel for topical use.Â <br/>Initial U.S. Approval 1963</title>
   <effectiveTime value="20241031"/>
   <setId root="3c25a3f9-52fc-448e-a044-f63b9dadcd4a"/>
   <versionNumber value="2"/>
   <author>
      <time/>
      <assignedEntity>
         <representedOrganization>
            <id extension="867220261" root="1.3.6.1.4.1.519.1"/>
            <name>Mayne Pharma Inc.</name>
            <assignedEntity>
               <assignedOrganization>
                  <assignedEntity>
                     <assignedOrganization>
                        <id extension="251676961" root="1.3.6.1.4.1.519.1"/>
                        <name>G Production Inc.</name>
                     </assignedOrganization>
                     <performance>
                        <actDefinition>
                           <code code="C43360" codeSystem="2.16.840.1.113883.3.26.1.1" displayName="manufacture"/>
                           <product>
                              <manufacturedProduct classCode="MANU">
                                 <manufacturedMaterialKind>
                                    <code code="68308-663" codeSystem="2.16.840.1.113883.6.69"/>
                                 </manufacturedMaterialKind>
                              </manufacturedProduct>
                           </product>
                        </actDefinition>
                     </performance>
                  </assignedEntity>
               </assignedOrganization>
            </assignedEntity>
         </representedOrganization>
      </assignedEntity>
   </author>
   <component>
      <structuredBody>
         <component>
            <section ID="ID_3a3882d1-5c3c-4317-bab2-f6195ff08e12">
               <id root="c22232e1-e256-4a7c-aff1-340bb0e683a5"/>
               <code code="48780-1" codeSystem="2.16.840.1.113883.6.1" displayName="SPL PRODUCT DATA ELEMENTS SECTION"/>
               <title/>
               <effectiveTime value="20250416"/>
               <subject>
                  <manufacturedProduct>
                     <manufacturedProduct>
                        <code code="68308-663" codeSystem="2.16.840.1.113883.6.69"/>
                        <name>Metronidazole<suffix/>
                        </name>
                        <formCode code="C42934" codeSystem="2.16.840.1.113883.3.26.1.1" displayName="GEL"/>
                        <asEntityWithGeneric>
                           <genericMedicine>
                              <name>metronidazole</name>
                           </genericMedicine>
                        </asEntityWithGeneric>
                        <ingredient classCode="ACTIB">
                           <quantity>
                              <numerator unit="mg" value="10"/>
                              <denominator unit="g" value="1"/>
                           </quantity>
                           <ingredientSubstance>
                              <code code="140QMO216E" codeSystem="2.16.840.1.113883.4.9"/>
                              <name>METRONIDAZOLE</name>
                              <activeMoiety>
                                 <activeMoiety>
                                    <code code="140QMO216E" codeSystem="2.16.840.1.113883.4.9"/>
                                    <name>Metronidazole</name>
                                 </activeMoiety>
                              </activeMoiety>
                           </ingredientSubstance>
                        </ingredient>
                        <ingredient classCode="IACT">
                           <ingredientSubstance>
                              <code code="JV039JZZ3A" codeSystem="2.16.840.1.113883.4.9"/>
                              <name>betadex</name>
                           </ingredientSubstance>
                        </ingredient>
                        <ingredient classCode="IACT">
                           <ingredientSubstance>
                              <code code="7FLD91C86K" codeSystem="2.16.840.1.113883.4.9"/>
                              <name>edetate disodium</name>
                           </ingredientSubstance>
                        </ingredient>
                        <ingredient classCode="IACT">
                           <ingredientSubstance>
                              <code code="A2I8C7HI9T" codeSystem="2.16.840.1.113883.4.9"/>
                              <name>methylparaben</name>
                           </ingredientSubstance>
                        </ingredient>
                        <ingredient classCode="IACT">
                           <ingredientSubstance>
                              <code code="25X51I8RD4" codeSystem="2.16.840.1.113883.4.9"/>
                              <name>niacinamide</name>
                           </ingredientSubstance>
                        </ingredient>
                        <ingredient classCode="IACT">
                           <ingredientSubstance>
                              <code code="HIE492ZZ3T" codeSystem="2.16.840.1.113883.4.9"/>
                              <name>phenoxyethanol</name>
                           </ingredientSubstance>
                        </ingredient>
                        <ingredient classCode="IACT">
                           <ingredientSubstance>
                              <code code="6DC9Q167V3" codeSystem="2.16.840.1.113883.4.9"/>
                              <name>propylene glycol</name>
                           </ingredientSubstance>
                        </ingredient>
                        <ingredient classCode="IACT">
                           <ingredientSubstance>
                              <code code="Z8IX2SC1OH" codeSystem="2.16.840.1.113883.4.9"/>
                              <name>propylparaben</name>
                           </ingredientSubstance>
                        </ingredient>
                        <ingredient classCode="IACT">
                           <ingredientSubstance>
                              <code code="059QF0KO0R" codeSystem="2.16.840.1.113883.4.9"/>
                              <name>water</name>
                           </ingredientSubstance>
                        </ingredient>
                        <asContent>
                           <quantity>
                              <numerator unit="g" value="55"/>
                              <denominator value="1"/>
                           </quantity>
                           <containerPackagedProduct>
                              <code codeSystem="2.16.840.1.113883.6.69"/>
                              <formCode code="C43174" codeSystem="2.16.840.1.113883.3.26.1.1" displayName="BOTTLE, PUMP"/>
                              <asContent>
                                 <quantity>
                                    <numerator unit="1" value="1"/>
                                    <denominator value="1"/>
                                 </quantity>
                                 <containerPackagedProduct>
                                    <code code="68308-663-55" codeSystem="2.16.840.1.113883.6.69"/>
                                    <formCode code="C43182" codeSystem="2.16.840.1.113883.3.26.1.1" displayName="CARTON"/>
                                 </containerPackagedProduct>
                                 <subjectOf>
                                    <marketingAct>
                                       <code code="C53292" codeSystem="2.16.840.1.113883.3.26.1.1"/>
                                       <statusCode code="active"/>
                                       <effectiveTime>
                                          <low value="20231110"/>
                                       </effectiveTime>
                                    </marketingAct>
                                 </subjectOf>
                              </asContent>
                           </containerPackagedProduct>
                           <subjectOf>
                              <characteristic>
                                 <code code="SPLCMBPRDTP" codeSystem="2.16.840.1.113883.1.11.19255"/>
                                 <value code="C112160" codeSystem="2.16.840.1.113883.3.26.1.1" displayName="Type 0: Not a Combination Product" xsi:type="CV"/>
                              </characteristic>
                           </subjectOf>
                        </asContent>
                        <asContent>
                           <quantity>
                              <numerator unit="g" value="60"/>
                              <denominator value="1"/>
                           </quantity>
                           <containerPackagedProduct>
                              <code codeSystem="2.16.840.1.113883.6.69"/>
                              <formCode code="C42794" codeSystem="2.16.840.1.113883.3.26.1.1" displayName="TUBE"/>
                              <asContent>
                                 <quantity>
                                    <numerator unit="1" value="1"/>
                                    <denominator value="1"/>
                                 </quantity>
                                 <containerPackagedProduct>
                                    <code code="68308-663-60" codeSystem="2.16.840.1.113883.6.69"/>
                                    <formCode code="C43182" codeSystem="2.16.840.1.113883.3.26.1.1" displayName="CARTON"/>
                                 </containerPackagedProduct>
                                 <subjectOf>
                                    <marketingAct>
                                       <code code="C53292" codeSystem="2.16.840.1.113883.3.26.1.1"/>
                                       <statusCode code="active"/>
                                       <effectiveTime>
                                          <low value="20250519"/>
                                       </effectiveTime>
                                    </marketingAct>
                                 </subjectOf>
                              </asContent>
                           </containerPackagedProduct>
                           <subjectOf>
                              <characteristic>
                                 <code code="SPLCMBPRDTP" codeSystem="2.16.840.1.113883.1.11.19255"/>
                                 <value code="C112160" codeSystem="2.16.840.1.113883.3.26.1.1" displayName="Type 0: Not a Combination Product" xsi:type="CV"/>
                              </characteristic>
                           </subjectOf>
                        </asContent>
                     </manufacturedProduct>
                     <subjectOf>
                        <marketingAct>
                           <code code="C53292" codeSystem="2.16.840.1.113883.3.26.1.1"/>
                           <statusCode code="active"/>
                           <effectiveTime>
                              <low value="20231110"/>
                           </effectiveTime>
                        </marketingAct>
                     </subjectOf>
                     <subjectOf>
                        <approval>
                           <id extension="NDA021789" root="2.16.840.1.113883.3.150"/>
                           <code code="C73605" codeSystem="2.16.840.1.113883.3.26.1.1" displayName="NDA authorized generic"/>
                           <author>
                              <territorialAuthority>
                                 <territory>
                                    <code code="USA" codeSystem="2.16.840.1.113883.5.28"/>
                                 </territory>
                              </territorialAuthority>
                           </author>
                        </approval>
                     </subjectOf>
                     <consumedIn>
                        <substanceAdministration>
                           <routeCode code="C38304" codeSystem="2.16.840.1.113883.3.26.1.1" displayName="TOPICAL"/>
                        </substanceAdministration>
                     </consumedIn>
                  </manufacturedProduct>
               </subject>
               <component>
                  <observationMedia ID="MM85743">
                     <text>55-g-carton-image</text>
                     <value mediaType="image/jpeg" xsi:type="ED">
                        <reference value="P57418-0 55g carton Mayne.jpg"/>
                     </value>
                  </observationMedia>
               </component>
               <component>
                  <observationMedia ID="MM88226">
                     <text>60g-carton-image</text>
                     <value mediaType="image/jpeg" xsi:type="ED">
                        <reference value="P58251-0 Metronidazole Gel 1 Carton Mayne2.jpg"/>
                     </value>
                  </observationMedia>
               </component>
            </section>
         </component>
         <component>
            <section ID="ID_9fb187a5-22c4-49be-9dc5-3bdf14c83070">
               <id root="31d1e356-4495-40af-8ee8-ed346827aac5"/>
               <code code="34067-9" codeSystem="2.16.840.1.113883.6.1" displayName="INDICATIONS &amp; USAGE SECTION"/>
               <title>1 INDICATIONSÂ AND USAGE</title>
               <text>
                  <paragraph>Metronidazole Gel, 1% is indicated for the topical treatment of inflammatory lesions of rosacea.Â </paragraph>
               </text>
               <effectiveTime value="20241031"/>
               <excerpt>
                  <highlight>
                     <text>
                        <paragraph>Metronidazole Gel, 1% is a nitroimidazole indicated for the topical treatment of inflammatory lesions of rosacea. (<linkHtml href="#ID_9fb187a5-22c4-49be-9dc5-3bdf14c83070">1</linkHtml>)</paragraph>
                     </text>
                  </highlight>
               </excerpt>
            </section>
         </component>
         <component>
            <section ID="ID_b5ca8a48-4f88-49ca-ab40-91d73f6bfeaa">
               <id root="9a1969c5-05e9-4376-9b23-d61c649afcc2"/>
               <code code="34068-7" codeSystem="2.16.840.1.113883.6.1" displayName="DOSAGE &amp; ADMINISTRATION SECTION"/>
               <title>2 DOSAGEÂ AND ADMINISTRATION</title>
               <text>
                  <list listType="unordered">
                     <item>Cleanse treated areas before the application of Metronidazole Gel.</item>
                     <item>Apply and rub in a thin film of Metronidazole Gel once daily to affected area(s).Â </item>
                     <item>Cosmetics may be applied after the application of Metronidazole Gel.Â </item>
                     <item>For topical use only, not for oral, ophthalmic, or intravaginal use.</item>
                  </list>
               </text>
               <effectiveTime value="20241031"/>
               <excerpt>
                  <highlight>
                     <text>
                        <list listType="unordered">
                           <item>Cleanse treated areas before the application of Metronidazole Gel. (<linkHtml href="#ID_b5ca8a48-4f88-49ca-ab40-91d73f6bfeaa">2</linkHtml>)</item>
                           <item>Apply and rub in a thin film of Metronidazole Gel once daily to affected area(s). (<linkHtml href="#ID_b5ca8a48-4f88-49ca-ab40-91d73f6bfeaa">2</linkHtml>)</item>
                           <item>Cosmetics may be applied after the application of Metronidazole Gel. (<linkHtml href="#ID_b5ca8a48-4f88-49ca-ab40-91d73f6bfeaa">2</linkHtml>)<br/>
                           </item>
                           <item>Not for oral, ophthalmic, or intravaginal use. (<linkHtml href="#ID_b5ca8a48-4f88-49ca-ab40-91d73f6bfeaa">2</linkHtml>) <br/>
                           </item>
                        </list>
                     </text>
                  </highlight>
               </excerpt>
            </section>
         </component>
         <component>
            <section ID="ID_1fe21904-baa8-460c-a17e-bc935bbf75b9">
               <id root="68581ddb-5383-49ca-8464-b3353fd08ebd"/>
               <code code="43678-2" codeSystem="2.16.840.1.113883.6.1" displayName="DOSAGE FORMS &amp; STRENGTHS SECTION"/>
               <title>3 DOSAGE FORMS AND STRENGTHS</title>
               <text>
                  <paragraph>Gel, 1%. Metronidazole Gel is a clear, colorless to pale yellow gel. Each gram of Metronidazole Gel contains 10 mg (1%) of metronidazole.<br/>
                  </paragraph>
               </text>
               <effectiveTime value="20241031"/>
               <excerpt>
                  <highlight>
                     <text>
                        <paragraph>Gel,1%</paragraph>
                     </text>
                  </highlight>
               </excerpt>
            </section>
         </component>
         <component>
            <section ID="ID_9e030690-cd99-4d75-80f6-bc811078f745">
               <id root="4f0fd3ae-e1a4-4ec4-8e48-377ad5aa5dca"/>
               <code code="34070-3" codeSystem="2.16.840.1.113883.6.1" displayName="CONTRAINDICATIONS SECTION"/>
               <title>4 CONTRAINDICATIONS</title>
               <text>
                  <paragraph>Metronidazole Gel is contraindicated in patients with a history of hypersensitivity to metronidazole or to any other ingredient in the formulation.</paragraph>
               </text>
               <effectiveTime value="20241031"/>
               <excerpt>
                  <highlight>
                     <text>
                        <paragraph>Metronidazole Gel is contraindicated in those patients with a history of hypersensitivity to metronidazole or to any other ingredient in this formulation. (<linkHtml href="#ID_9e030690-cd99-4d75-80f6-bc811078f745">4</linkHtml>)<br/>
                        </paragraph>
                     </text>
                  </highlight>
               </excerpt>
            </section>
         </component>
         <component>
            <section ID="ID_2aa9bbc9-3fc0-4e51-8788-5c8dca818ca4">
               <id root="a43f4e0f-c178-48e1-b7e9-ac3a2f970100"/>
               <code code="43685-7" codeSystem="2.16.840.1.113883.6.1" displayName="WARNINGS AND PRECAUTIONS SECTION"/>
               <title>5 WARNINGS AND PRECAUTIONS</title>
               <text>
                  <br/>
               </text>
               <effectiveTime value="20241031"/>
               <excerpt>
                  <highlight>
                     <text>
                        <list ID="SPLSERV-286c84f8-509f-490d-a8eb-2ce9b2183354" listType="unordered">
                           <item>
                              <content styleCode="italics">Neurologic Disease:</content> Peripheral neuropathy, characterized by numbness or paresthesia of an extremity has been reported in patients treated with systemic metronidazole. Peripheral neuropathy has been reported with the post approval use ofÂ topical metronidazole. Immediately reevaluate Metronidazole Gel if abnormal neurologic signs appear. (<linkHtml href="#ID_bdb6ae47-236c-4755-85d7-bd8ffa6bdff4">5.1</linkHtml>)Â </item>
                           <item>
                              <content styleCode="italics">Blood Dyscrasias:</content> Metronidazole Gel is a nitroimidazole; use with care in patients with evidence of, or history of, blood dyscrasia. (<linkHtml href="#ID_d76016ad-1269-4cf2-ad92-7fa12133432f">5.2</linkHtml>)Â </item>
                           <item>
                              <content styleCode="italics">Contact Dermatitis:</content> If dermatitis occurs, patients may need to discontinue use. (<linkHtml href="#ID_4bbb0ccd-9dbb-4fe9-a7d4-7c2f1cdadfd9">5.3</linkHtml>)Â </item>
                           <item>
                              <content styleCode="italics">Eye Irritation:</content> Topical metronidazole has been reported to cause tearing of the eyes. Avoid contact with the eyes. (<linkHtml href="#ID_1c03a271-f1b7-4b17-9588-5868cdb097fd">5.4</linkHtml>)<br/>
                           </item>
                        </list>
                     </text>
                  </highlight>
               </excerpt>
               <component>
                  <section ID="ID_bdb6ae47-236c-4755-85d7-bd8ffa6bdff4">
                     <id root="045c5d61-5d8c-4ade-a1d5-e052110c15b5"/>
                     <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                     <title>5.1 Neurologic Disease</title>
                     <text>
                        <paragraph>Peripheral neuropathy, characterized by numbness or paresthesia of an extremity, has been reported in patients treated with systemic metronidazole. Peripheral neuropathy has been reported with the post approval use of topical metronidazole. Immediately reevaluate Metronidazole Gel therapy if abnormal neurologic signs appear. Administer metronidazole with caution to patients with central nervous system diseases.</paragraph>
                     </text>
                     <effectiveTime value="20241031"/>
                  </section>
               </component>
               <component>
                  <section ID="ID_d76016ad-1269-4cf2-ad92-7fa12133432f">
                     <id root="83b8ac3a-c7ca-4449-9ea3-ffd54bb866db"/>
                     <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                     <title>5.2 Blood Dyscrasias</title>
                     <text>
                        <paragraph>Metronidazole is a nitroimidazole; use with care in patients with evidence of, or history of, blood dyscrasia.</paragraph>
                     </text>
                     <effectiveTime value="20241031"/>
                  </section>
               </component>
               <component>
                  <section ID="ID_4bbb0ccd-9dbb-4fe9-a7d4-7c2f1cdadfd9">
                     <id root="4df7b788-bc08-44c1-b9d3-bb838fae011b"/>
                     <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                     <title>5.3 Contact Dermatitis</title>
                     <text>
                        <paragraph>Irritant and allergic contact dermatitis have been reported with Metronidazole Gel. If dermatitis occurs, patients may need to discontinue use.</paragraph>
                     </text>
                     <effectiveTime value="20241031"/>
                  </section>
               </component>
               <component>
                  <section ID="ID_1c03a271-f1b7-4b17-9588-5868cdb097fd">
                     <id root="682af84f-6563-4edc-8058-445a7802ea98"/>
                     <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                     <title>5.4 Eye Irritation</title>
                     <text>
                        <paragraph>Topical metronidazole has been reported to cause tearing of the eyes.Â  Avoid contact with the eyes.</paragraph>
                     </text>
                     <effectiveTime value="20241031"/>
                  </section>
               </component>
            </section>
         </component>
         <component>
            <section ID="ID_3755bfd4-acdf-4764-a793-5246b6793f74">
               <id root="659397e4-7fc4-48ba-8eab-c411358e88fd"/>
               <code code="34084-4" codeSystem="2.16.840.1.113883.6.1" displayName="ADVERSE REACTIONS SECTION"/>
               <title>6 ADVERSE REACTIONS</title>
               <text>
                  <paragraph>The following clinically significant adverse reactions are described elsewhere in the labeling:</paragraph>
                  <list listType="unordered">
                     <item>Neurologic Disease <content styleCode="italics">[see Warnings and Precautions (5.1)]<br/>
                        </content>Contact Dermatitis <content styleCode="italics">[see Warnings and Precautions (5.3)]</content>Â </item>
                     <item>Eye Irritation <content styleCode="italics">[see Warnings and Precautions (5.4)]</content>
                     </item>
                  </list>
                  <br/>
               </text>
               <effectiveTime value="20241031"/>
               <excerpt>
                  <highlight>
                     <text>
                        <paragraph>Most common adverse reactions (incidence &gt; 2%) are nasopharyngitis, upper respiratory tract infection, and headache. (<linkHtml href="#ID_3755bfd4-acdf-4764-a793-5246b6793f74">6</linkHtml>)<br/>
                        </paragraph>
                        <paragraph>
                           <content styleCode="bold">To report SUSPECTED ADVERSE REACTIONS, contact Mayne Pharma, at 1-844-825-8500, or FDA at 1-800-FDA-1088 orÂ <content styleCode="italics">www.fda.gov/medwatch</content>
                           </content>
                        </paragraph>
                     </text>
                  </highlight>
               </excerpt>
               <component>
                  <section>
                     <id root="24ee8995-c9db-4710-98b0-d68cfb14e439"/>
                     <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                     <title>6.1 Clinical Trials Experience</title>
                     <text>
                        <paragraph>Because clinical trials are conducted under widely varying conditions, adverse reaction rates observed in the clinical trials of a drug cannot be directly compared to rates in the clinical trials of another drug and may not reflect the rates observed in practice. <br/>In a controlled clinical trial, 557 subjects used Metronidazole Gel and 189 subjects used the gel vehicle once daily for up to 10 weeks. The following table summarizes selected adverse reactions that occurred at a rate of â¥1% and at a higher rate than vehicle:</paragraph>
                        <table ID="SPLSERV-45481a85-c661-48d0-ab18-a65a33461247" styleCode="Noautorules" width="90%">
                           <caption>Table 1: Adverse Reactions That Occurred at a Rate of â¥1% and Higher Than Vehicle in Subjects Treated with Metronidazole Gel for Up to 10 Weeks</caption>
                           <colgroup>
                              <col width="50%"/>
                              <col width="25%"/>
                              <col width="25%"/>
                           </colgroup>
                           <thead>
                              <tr>
                                 <td align="left" styleCode="Botrule Lrule Rrule Toprule">
                                    <content styleCode="bold">Preferred Term</content>
                                 </td>
                                 <td align="center" styleCode="Botrule Lrule Rrule Toprule">
                                    <content styleCode="bold">Metronidazole Gel</content>
                                 </td>
                                 <td align="center" styleCode="Botrule Lrule Rrule Toprule">
                                    <content styleCode="bold">Gel Vehicle</content>
                                 </td>
                              </tr>
                           </thead>
                           <tbody>
                              <tr>
                                 <td align="left" styleCode="Botrule Lrule Rrule Toprule">Â Â  Influenza</td>
                                 <td align="center" styleCode="Botrule Lrule Rrule Toprule">8 (1.4)</td>
                                 <td align="center" styleCode="Botrule Lrule Rrule Toprule">1 (0.5)</td>
                              </tr>
                              <tr>
                                 <td align="left" styleCode="Botrule Lrule Rrule Toprule">Â Â  Upper respiratory tract infection</td>
                                 <td align="center" styleCode="Botrule Lrule Rrule Toprule">14 (2.5)</td>
                                 <td align="center" styleCode="Botrule Lrule Rrule Toprule">4 (2.1)</td>
                              </tr>
                              <tr>
                                 <td align="left" styleCode="Botrule Lrule Rrule Toprule">Â Â  Urinary tract infection</td>
                                 <td align="center" styleCode="Botrule Lrule Rrule Toprule">6 (1.1)</td>
                                 <td align="center" styleCode="Botrule Lrule Rrule Toprule">1 (0.5)</td>
                              </tr>
                              <tr>
                                 <td align="left" styleCode="Botrule Lrule Rrule Toprule">Â Â  Headache</td>
                                 <td align="center" styleCode="Botrule Lrule Rrule Toprule">12 (2.2)</td>
                                 <td align="center" styleCode="Botrule Lrule Rrule Toprule">1 (0.5)</td>
                              </tr>
                              <tr>
                                 <td align="left" styleCode="Botrule Lrule Rrule Toprule">Â Â  Contact dermatitis</td>
                                 <td align="center" styleCode="Botrule Lrule Rrule Toprule">7 (1.3)</td>
                                 <td align="center" styleCode="Botrule Lrule Rrule Toprule">1 (0.5)</td>
                              </tr>
                              <tr>
                                 <td align="left" styleCode="Botrule Lrule Rrule Toprule">Â Â  Hypertension</td>
                                 <td align="center" styleCode="Botrule Lrule Rrule Toprule">6 (1.1)</td>
                                 <td align="center" styleCode="Botrule Lrule Rrule Toprule">1 (0.5)</td>
                              </tr>
                           </tbody>
                        </table>
                        <table ID="SPLSERV-a3f65b4f-5b95-41e7-9530-9cea8c8fde0f" width="90%">
                           <caption>Table 2: Local Cutaneous Signs and Symptoms of Irritation That Were Worse Than BaselineÂ in Subjects Treated with Metronidazole Gel for Up to 10 Weeks</caption>
                           <colgroup>
                              <col width="50%"/>
                              <col width="25%"/>
                              <col width="25%"/>
                           </colgroup>
                           <thead>
                              <tr>
                                 <td align="left" styleCode="Botrule Lrule Rrule Toprule"/>
                                 <td align="center" styleCode="Botrule Lrule Rrule Toprule">
                                    <content styleCode="bold">Metronidazole Gel</content>
                                 </td>
                                 <td align="center" styleCode="Botrule Lrule Rrule Toprule">
                                    <content styleCode="bold">Gel Vehicle</content>
                                 </td>
                              </tr>
                           </thead>
                           <tbody>
                              <tr>
                                 <td align="left" styleCode="Botrule Lrule Rrule Toprule">
                                    <content styleCode="bold">Sign/Symptom</content>
                                 </td>
                                 <td align="center" styleCode="Botrule Lrule Rrule Toprule">
                                    <content styleCode="bold">N= 544 N (%)</content>
                                 </td>
                                 <td align="center" styleCode="Botrule Lrule Rrule Toprule">
                                    <content styleCode="bold">N= 184 N (%)</content>
                                 </td>
                              </tr>
                              <tr>
                                 <td align="left" styleCode="Botrule Lrule Rrule Toprule">
                                    <content styleCode="bold">Dryness</content>
                                 </td>
                                 <td align="center" styleCode="Botrule Lrule Rrule Toprule">
                                    <content styleCode="bold">138 (25.4)</content>
                                 </td>
                                 <td align="center" styleCode="Botrule Lrule Rrule Toprule">
                                    <content styleCode="bold">63 (34.2)</content>
                                 </td>
                              </tr>
                              <tr>
                                 <td align="left" styleCode="Botrule Lrule Rrule Toprule">Â Â  Mild</td>
                                 <td align="center" styleCode="Botrule Lrule Rrule Toprule">93 (17.1)</td>
                                 <td align="center" styleCode="Botrule Lrule Rrule Toprule">41 (22.3)</td>
                              </tr>
                              <tr>
                                 <td align="left" styleCode="Botrule Lrule Rrule Toprule">Â Â  Moderate</td>
                                 <td align="center" styleCode="Botrule Lrule Rrule Toprule">42 (7.7)</td>
                                 <td align="center" styleCode="Botrule Lrule Rrule Toprule">20 (10.9)</td>
                              </tr>
                              <tr>
                                 <td align="left" styleCode="Botrule Lrule Rrule Toprule">Â Â  Severe</td>
                                 <td align="center" styleCode="Botrule Lrule Rrule Toprule">3 (0.6)</td>
                                 <td align="center" styleCode="Botrule Lrule Rrule Toprule">2 (1.1)</td>
                              </tr>
                              <tr>
                                 <td align="left" styleCode="Botrule Lrule Rrule Toprule">
                                    <content styleCode="bold">Scaling</content>
                                 </td>
                                 <td align="center" styleCode="Botrule Lrule Rrule Toprule">
                                    <content styleCode="bold">134 (24.6)</content>
                                 </td>
                                 <td align="center" styleCode="Botrule Lrule Rrule Toprule">
                                    <content styleCode="bold">60 (32.6)</content>
                                 </td>
                              </tr>
                              <tr>
                                 <td align="left" styleCode="Botrule Lrule Rrule Toprule">Â Â  Mild</td>
                                 <td align="center" styleCode="Botrule Lrule Rrule Toprule">88 (16.2)</td>
                                 <td align="center" styleCode="Botrule Lrule Rrule Toprule">32 (17.4)</td>
                              </tr>
                              <tr>
                                 <td align="left" styleCode="Botrule Lrule Rrule Toprule">Â Â  Moderate</td>
                                 <td align="center" styleCode="Botrule Lrule Rrule Toprule">43 (7.9)</td>
                                 <td align="center" styleCode="Botrule Lrule Rrule Toprule">27 (14.7)</td>
                              </tr>
                              <tr>
                                 <td align="left" styleCode="Botrule Lrule Rrule Toprule">Â Â  Severe</td>
                                 <td align="center" styleCode="Botrule Lrule Rrule Toprule">3 (0.6)</td>
                                 <td align="center" styleCode="Botrule Lrule Rrule Toprule">1 (0.5)</td>
                              </tr>
                              <tr>
                                 <td align="left" styleCode="Botrule Lrule Rrule Toprule">
                                    <content styleCode="bold">Pruritus</content>
                                 </td>
                                 <td align="center" styleCode="Botrule Lrule Rrule Toprule">
                                    <content styleCode="bold">86 (15.8)</content>
                                 </td>
                                 <td align="center" styleCode="Botrule Lrule Rrule Toprule">
                                    <content styleCode="bold">35 (19.0)</content>
                                 </td>
                              </tr>
                              <tr>
                                 <td align="left" styleCode="Botrule Lrule Rrule Toprule">Â Â  Mild</td>
                                 <td align="center" styleCode="Botrule Lrule Rrule Toprule">53 (9.7)</td>
                                 <td align="center" styleCode="Botrule Lrule Rrule Toprule">21 (11.4)</td>
                              </tr>
                              <tr>
                                 <td align="left" styleCode="Botrule Lrule Rrule Toprule">Â Â  Moderate</td>
                                 <td align="center" styleCode="Botrule Lrule Rrule Toprule">27 (5.0)</td>
                                 <td align="center" styleCode="Botrule Lrule Rrule Toprule">13 (7.1)</td>
                              </tr>
                              <tr>
                                 <td align="left" styleCode="Botrule Lrule Rrule Toprule">Â Â  Severe</td>
                                 <td align="center" styleCode="Botrule Lrule Rrule Toprule">6 (1.1)</td>
                                 <td align="center" styleCode="Botrule Lrule Rrule Toprule">1 (0.5)</td>
                              </tr>
                              <tr>
                                 <td align="left" styleCode="Botrule Lrule Rrule Toprule">
                                    <content styleCode="bold">Stinging/burning</content>
                                 </td>
                                 <td align="center" styleCode="Botrule Lrule Rrule Toprule">
                                    <content styleCode="bold">56 (10.3)</content>
                                 </td>
                                 <td align="center" styleCode="Botrule Lrule Rrule Toprule">
                                    <content styleCode="bold">28 (15.2)</content>
                                 </td>
                              </tr>
                              <tr>
                                 <td align="left" styleCode="Botrule Lrule Rrule Toprule">Â Â  Mild</td>
                                 <td align="center" styleCode="Botrule Lrule Rrule Toprule">39 (7.2)</td>
                                 <td align="center" styleCode="Botrule Lrule Rrule Toprule">18 (9.8)</td>
                              </tr>
                              <tr>
                                 <td align="left" styleCode="Botrule Lrule Rrule Toprule">Â Â  Moderate</td>
                                 <td align="center" styleCode="Botrule Lrule Rrule Toprule">7 (1.3)</td>
                                 <td align="center" styleCode="Botrule Lrule Rrule Toprule">9 (4.9)</td>
                              </tr>
                              <tr>
                                 <td align="left" styleCode="Botrule Lrule Rrule Toprule">Â Â  Severe</td>
                                 <td align="center" styleCode="Botrule Lrule Rrule Toprule">10 (1.8)</td>
                                 <td align="center" styleCode="Botrule Lrule Rrule Toprule">1 (0.5)</td>
                              </tr>
                           </tbody>
                        </table>
                        <paragraph>The following additional adverse experiences have been reported with the topical use of metronidazole: transient redness, metallic taste, tingling or numbness of extremities, and nausea.<br/>
                        </paragraph>
                     </text>
                     <effectiveTime value="20241031"/>
                  </section>
               </component>
               <component>
                  <section>
                     <id root="e5d6c196-cd7e-471a-8fc6-15fcf8144517"/>
                     <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                     <title>6.2 Post Marketing Experience</title>
                     <text>
                        <paragraph>The following adverse reaction has been identified during post- approval use of topical metronidazole. Because this reaction is reported voluntarily from a population of uncertain size, it is not always possible to reliably estimate the frequency or establish a causal relationship to drug exposure.<br/>
                           <br/>
                           <content styleCode="italics">Nervous System Disorders:</content> Peripheral neuropathyÂ <br/>
                           <content styleCode="italics">Ophthalmic Adverse Reactions:</content> Tearing of the eyes</paragraph>
                     </text>
                     <effectiveTime value="20241031"/>
                  </section>
               </component>
            </section>
         </component>
         <component>
            <section ID="ID_1a1885e7-2ab6-4561-bf87-5bfbdbadeee5">
               <id root="950f05d4-5669-4eaa-870f-63d36287645f"/>
               <code code="34073-7" codeSystem="2.16.840.1.113883.6.1" displayName="DRUG INTERACTIONS SECTION"/>
               <title>7 DRUG INTERACTIONS</title>
               <text>
                  <paragraph>Oral metronidazole has been reported to potentiate the anticoagulant effect of coumarin and warfarin, resulting in a prolongation of prothrombin time. Use caution when prescribing for patients who are receiving anticoagulant treatment.</paragraph>
               </text>
               <effectiveTime value="20241031"/>
               <excerpt>
                  <highlight>
                     <text>
                        <paragraph>Oral metronidazole has been reported to potentiate the anticoagulant effect of coumarin and warfarin, resulting in a prolongation of prothrombin time. Use caution when administering Metronidazole Gel concomitantly to patients who are receiving anticoagulant treatment. (<linkHtml href="#ID_1a1885e7-2ab6-4561-bf87-5bfbdbadeee5">7</linkHtml>)<br/>
                        </paragraph>
                     </text>
                  </highlight>
               </excerpt>
            </section>
         </component>
         <component>
            <section ID="ID_69f1432f-c809-42c6-b0f5-16886d91d1e8">
               <id root="d83c8514-4ec2-40e1-9b7d-91f5ff0afd9a"/>
               <code code="43684-0" codeSystem="2.16.840.1.113883.6.1" displayName="USE IN SPECIFIC POPULATIONS SECTION"/>
               <title>8 USE IN SPECIFIC POPULATIONS</title>
               <text>
                  <br/>
               </text>
               <effectiveTime value="20241031"/>
               <excerpt>
                  <highlight>
                     <text>
                        <list listType="unordered">
                           <item>Lactation: Breastfeeding not recommended. <linkHtml href="#ID_dfb59ab6-aede-4468-b67e-973b07edba23">(8.2</linkHtml>)</item>
                        </list>
                     </text>
                  </highlight>
               </excerpt>
               <component>
                  <section>
                     <id root="b3bcfdbf-eef9-4713-b27e-a62398167ed8"/>
                     <code code="42228-7" codeSystem="2.16.840.1.113883.6.1" displayName="PREGNANCY SECTION"/>
                     <title>8.1 Pregnancy</title>
                     <text>
                        <paragraph>
                           <content styleCode="underline">Risk Summary</content>
                           <br/>Available data have not established an association with metronidazole use during pregnancy and major birth defects, miscarriage or other adverse maternal or fetal outcomes. No fetotoxicity was observed after oral administration of metronidazole in pregnant rats or mice. The available data do not allow the calculation of relevant comparisons between the systemic exposures of metronidazole observed in animal studies to the systemic exposures that would be expected in humans after topical use of Metronidazole Gel.<br/>
                           <br/>The background risk of major birth defects and miscarriage for the indicated population is unknown. All pregnancies have a background risk of birth defect, loss, or other adverse outcomes. In the U.S. general population, the estimated background risk of major birth defects and miscarriage in clinically recognized pregnancies is 2-4% and 15-20%, respectively.<br/>
                        </paragraph>
                     </text>
                     <effectiveTime value="20241031"/>
                  </section>
               </component>
               <component>
                  <section ID="ID_dfb59ab6-aede-4468-b67e-973b07edba23">
                     <id root="8aebf701-6cfa-4886-a70f-f560e0a62f47"/>
                     <code code="34079-4" codeSystem="2.16.840.1.113883.6.1" displayName="LABOR &amp; DELIVERY SECTION"/>
                     <title>8.2 Lactation</title>
                     <text>
                        <paragraph>
                           <content styleCode="italics">Risk Summary</content>
                           <br/>It is not known whether metronidazole is present in human milk after topical administration. Published literature reports the presence of metronidazole in human milk after oral administration. There are no data on the effects of metronidazole on milk production. Because of the potential for serious adverse reactions, advise patients that breastfeeding is not recommended during treatment with Metronidazole Gel.</paragraph>
                     </text>
                     <effectiveTime value="20241031"/>
                  </section>
               </component>
               <component>
                  <section ID="ID_936efbd0-8de3-45db-8d75-db517a143503">
                     <id root="fe10124b-1e78-436d-92a7-96b9b741b508"/>
                     <code code="34081-0" codeSystem="2.16.840.1.113883.6.1" displayName="PEDIATRIC USE SECTION"/>
                     <title>8.4 Pediatric Use</title>
                     <text>
                        <paragraph>Safety and effectiveness of Metronidazole Gel have not been established in pediatric patients.</paragraph>
                     </text>
                     <effectiveTime value="20241031"/>
                  </section>
               </component>
               <component>
                  <section ID="ID_93763309-90dc-4fc3-b96a-272f1b1303f0">
                     <id root="570d55c4-ea77-4e2d-bcc6-ca92a0002f82"/>
                     <code code="34082-8" codeSystem="2.16.840.1.113883.6.1" displayName="GERIATRIC USE SECTION"/>
                     <title>8.5 Geriatric Use</title>
                     <text>
                        <paragraph>Sixty-six subjects aged 65 years and older were treated with Metronidazole Gel in the clinical study. No overall differences in safety or effectiveness were observed between these subjects and younger subjects, and other reported clinical experience has not identified differences in responses between the elderly and younger patients, but greater sensitivity of some older individuals cannot be ruled out..</paragraph>
                     </text>
                     <effectiveTime value="20241031"/>
                  </section>
               </component>
            </section>
         </component>
         <component>
            <section ID="ID_5bf5602f-b547-4163-8c97-c1d88edbd1c1">
               <id root="f2d77d02-d32e-494b-a1a3-2c2de49a7581"/>
               <code code="34089-3" codeSystem="2.16.840.1.113883.6.1" displayName="DESCRIPTION SECTION"/>
               <title>11 DESCRIPTION</title>
               <text>
                  <paragraph>Metronidazole topical gel, 1% is a nitroimidazole for topical use. Metronidazole Gel is a clear, colorless to pale yellow, aqueous gel. Each gram contains 10 mg of metronidazole. Chemically, metronidazole is 2-methyl-5-nitro-1 <content styleCode="bold">
                        <content styleCode="italics">H</content>
                     </content>-imidazole-1-ethanol. The molecular formula for metronidazole is C<sub>6</sub>H<sub>9</sub>N<sub>3</sub>O<sub>3</sub>. It has the following structural formula:</paragraph>
                  <paragraph>
                     <renderMultiMedia referencedObject="SPLSERV-ca9a51bb-6f93-4a7f-81e8-ef0c0e517c9f"/>
                  </paragraph>
                  <paragraph>Metronidazole has a molecular weight of 171.16. It is a white to pale yellow crystalline powder. It is slightly soluble in alcohol and has solubility in water of 10 mg/mL at 20ËC. Metronidazole belongs to the nitroimidazole class of compounds.<br/>The inactive ingredients are betadex, edetate disodium, hydroxyethyl cellulose, methylparaben, niacinamide, phenoxyethanol, propylene glycol, propylparaben and purified water.</paragraph>
               </text>
               <effectiveTime value="20241031"/>
               <component>
                  <observationMedia ID="SPLSERV-ca9a51bb-6f93-4a7f-81e8-ef0c0e517c9f" classCode="OBS" moodCode="EVN">
                     <text>Structural Formula</text>
                     <value mediaType="image/jpeg" xsi:type="ED">
                        <reference value="metronidazole-struc-1.jpg"/>
                     </value>
                  </observationMedia>
               </component>
            </section>
         </component>
         <component>
            <section ID="ID_f268a49e-8f8c-4f33-9d0a-7b5aef9d4f83">
               <id root="44981593-127c-4115-ae91-d7b13c972c80"/>
               <code code="34090-1" codeSystem="2.16.840.1.113883.6.1" displayName="CLINICAL PHARMACOLOGY SECTION"/>
               <title>12 CLINICAL PHARMACOLOGY</title>
               <text>
                  <br/>
               </text>
               <effectiveTime value="20241031"/>
               <component>
                  <section>
                     <id root="e6bf7256-1448-4dae-ba61-dc4023063c9e"/>
                     <code code="43679-0" codeSystem="2.16.840.1.113883.6.1" displayName="MECHANISM OF ACTION SECTION"/>
                     <title>12.1 Mechanism of Action</title>
                     <text>
                        <paragraph>The mechanism of action of metronidazole in the treatment of rosacea is unknown.</paragraph>
                     </text>
                     <effectiveTime value="20241031"/>
                  </section>
               </component>
               <component>
                  <section>
                     <id root="f5dd4557-90bb-4a54-8210-a3d8f42511f6"/>
                     <code code="43681-6" codeSystem="2.16.840.1.113883.6.1" displayName="PHARMACODYNAMICS SECTION"/>
                     <title>12.2 Pharmacodynamics</title>
                     <text>
                        <paragraph>The pharmacodynamics of metronidazole in association with the treatment of rosacea are unknown.<br/>
                           <content styleCode="italics">Cardiac Electrophysiology:</content> The effect of Metronidazole Gel on the QTc interval has not been adequately characterized.</paragraph>
                     </text>
                     <effectiveTime value="20241031"/>
                  </section>
               </component>
               <component>
                  <section>
                     <id root="0562dac1-f30a-415f-be72-318d0d83b4d8"/>
                     <code code="43682-4" codeSystem="2.16.840.1.113883.6.1" displayName="PHARMACOKINETICS SECTION"/>
                     <title>12.3 Pharmacokinetics</title>
                     <text>
                        <paragraph>Topical administration of a one gram dose of Metronidazole Gel to the face of 13 patients with moderate to severe rosacea once daily for 7 days resulted in a mean Â± SD C<sub>max</sub> of metronidazole of 32 Â± 9 ng/mL.Â  The mean Â± SD AUC<sub>(0-24)</sub> was 595 Â± 154 ng*hr/mL. The mean C<sub>max</sub> and AUC<sub>(0-24)</sub> are less than 1% of the value reported for a single 250 mg oral dose of metronidazole. The time to maximum plasma concentration (T<sub>max</sub>) was 6-10 hours after topical application.</paragraph>
                     </text>
                     <effectiveTime value="20241031"/>
                  </section>
               </component>
            </section>
         </component>
         <component>
            <section ID="ID_b815eadc-c9ec-41e5-8c71-a56004e820f5">
               <id root="4a4c6d2a-bd75-44ee-ad95-9c24b8266b02"/>
               <code code="43680-8" codeSystem="2.16.840.1.113883.6.1" displayName="NONCLINICAL TOXICOLOGY SECTION"/>
               <title>13 NONCLINICAL TOXICOLOGY</title>
               <text>
                  <br/>
               </text>
               <effectiveTime value="20241031"/>
               <component>
                  <section>
                     <id root="67d1d7b5-4a83-46f0-ba3f-eafbb01fc292"/>
                     <code code="34083-6" codeSystem="2.16.840.1.113883.6.1" displayName="CARCINOGENESIS &amp; MUTAGENESIS &amp; IMPAIRMENT OF FERTILITY SECTION"/>
                     <title>13.1 Carcinogenesis, Mutagenesis, Impairment of Fertility</title>
                     <text>
                        <paragraph>Metronidazole has shown evidence of carcinogenic activity in a number of studies involving chronic, oral administration in mice and rats, but not in studies involving hamsters.<br/> In several long-term studies in mice, oral doses of approximately 225 mg/m<sup>2</sup>/day or greater were associated with an increase in pulmonary tumors and lymphomas. Several long-term oral studies in the rat have shown statistically significant increases in mammary and hepatic tumors at doses &gt;885 mg/m<sup>2</sup>/day. <br/>Metronidazole has shown evidence of mutagenic activity in several in vitro bacterial assay systems. In addition, a dose-related increase in the frequency of micronuclei was observed in mice after intraperitoneal injections. An increase in chromosomal aberrations in peripheral blood lymphocytes was reported in patients with Crohnâs disease who were treated with 200 to 1200 mg/day of metronidazole for 1 to 24 months. However, in another study, no increase in chromosomal aberrations in circulating lymphocytes was observed in patients with Crohnâs disease treated with the drug for 8 months.<br/>
                        </paragraph>
                     </text>
                     <effectiveTime value="20241031"/>
                  </section>
               </component>
            </section>
         </component>
         <component>
            <section ID="ID_7ce46344-9bc6-4266-8a59-0136d2b7bcd2">
               <id root="398a5332-e9fe-447d-8ff0-ef86d57b1296"/>
               <code code="34092-7" codeSystem="2.16.840.1.113883.6.1" displayName="CLINICAL STUDIES SECTION"/>
               <title>14 CLINICAL STUDIES</title>
               <text>
                  <paragraph>In a randomized, vehicle-controlled trial, 746 subjects with rosacea were treated with Metronidazole Gel or vehicle once daily for 10 weeks. Most subjects had a disease severity score of 3 (âmoderateâ) on the 5-point Investigator Global Assessment (IGA) scale, with 8 to 50 inflammatory lesions and no more than two nodules at baseline. The co-primary efficacy endpoints were the percent reduction in inflammatory lesion counts and percentage of subjects with success on IGA, defined as an IGA score of 0 (âclearâ) or 1 ( âalmost clearâ) at Week 10. <br/>
                     <br/>The efficacy results are shown in the following table:<br/>
                  </paragraph>
                  <br/>
                  <table ID="SPLSERV-d2e85554-dfe8-44ec-b079-d0d717939ebc" frame="box" width="90%">
                     <caption>Table 3: Inflammatory Lesion Counts and Global Scores in Subjects with Rosacea at Week 10 in a Clinical Trial </caption>
                     <thead>
                        <tr>
                           <td align="left" rowspan="2" styleCode="Botrule Lrule Rrule Toprule">Â </td>
                           <td align="center" colspan="2" styleCode="Botrule Lrule Rrule Toprule">Metronidazole Gel</td>
                           <td align="center" colspan="2" styleCode="Botrule Lrule Rrule Toprule">Vehicle</td>
                        </tr>
                        <tr>
                           <td align="center" styleCode="Botrule Lrule Rrule Toprule">N</td>
                           <td align="center" styleCode="Botrule Lrule Rrule Toprule">Results N (%)</td>
                           <td align="center" styleCode="Botrule Lrule Rrule Toprule">N</td>
                           <td align="center" styleCode="Botrule Lrule Rrule Toprule">Results N (%)</td>
                        </tr>
                     </thead>
                     <tbody>
                        <tr>
                           <td align="center" styleCode="Botrule Lrule Rrule Toprule">
                              <content styleCode="bold">Inflammatory lesions</content>
                           </td>
                           <td align="center" styleCode="Botrule Lrule Rrule Toprule">557</td>
                           <td align="center" styleCode="Botrule Lrule Rrule Toprule">Â </td>
                           <td align="center" styleCode="Botrule Lrule Rrule Toprule">189</td>
                           <td align="center" styleCode="Botrule Lrule Rrule Toprule">Â </td>
                        </tr>
                        <tr>
                           <td align="center" styleCode="Botrule Lrule Rrule Toprule">Baseline, mean count</td>
                           <td align="center" styleCode="Botrule Lrule Rrule Toprule">Â </td>
                           <td align="center" styleCode="Botrule Lrule Rrule Toprule">18.3</td>
                           <td align="center" styleCode="Botrule Lrule Rrule Toprule">Â </td>
                           <td align="center" styleCode="Botrule Lrule Rrule Toprule">18.4</td>
                        </tr>
                        <tr>
                           <td align="center" styleCode="Botrule Lrule Rrule Toprule">Week-10, mean count</td>
                           <td align="center" styleCode="Botrule Lrule Rrule Toprule">Â </td>
                           <td align="center" styleCode="Botrule Lrule Rrule Toprule">8.9</td>
                           <td align="center" styleCode="Botrule Lrule Rrule Toprule">Â </td>
                           <td align="center" styleCode="Botrule Lrule Rrule Toprule">12.8</td>
                        </tr>
                        <tr>
                           <td align="center" styleCode="Botrule Lrule Rrule Toprule">Reduction</td>
                           <td align="center" styleCode="Botrule Lrule Rrule Toprule">Â </td>
                           <td align="center" styleCode="Botrule Lrule Rrule Toprule">9.4 (50.7)</td>
                           <td align="center" styleCode="Botrule Lrule Rrule Toprule">Â </td>
                           <td align="center" styleCode="Botrule Lrule Rrule Toprule">5.6 (32.6)</td>
                        </tr>
                        <tr>
                           <td align="center" styleCode="Botrule Lrule Rrule Toprule">
                              <content styleCode="bold">Investigator Global Assessment</content>
                           </td>
                           <td align="center" styleCode="Botrule Lrule Rrule Toprule">557</td>
                           <td align="center" styleCode="Botrule Lrule Rrule Toprule">Â </td>
                           <td align="center" styleCode="Botrule Lrule Rrule Toprule">189</td>
                           <td align="center" styleCode="Botrule Lrule Rrule Toprule">Â </td>
                        </tr>
                        <tr>
                           <td align="center" styleCode="Botrule Lrule Rrule Toprule">Subject clear or almost clear</td>
                           <td align="center" styleCode="Botrule Lrule Rrule Toprule">Â </td>
                           <td align="center" styleCode="Botrule Lrule Rrule Toprule">214 (38.42)</td>
                           <td align="center" styleCode="Botrule Lrule Rrule Toprule">Â </td>
                           <td align="center" styleCode="Botrule Lrule Rrule Toprule">52 (27.51)</td>
                        </tr>
                        <tr>
                           <td align="center" styleCode="Botrule Lrule Rrule Toprule">Subject with no change</td>
                           <td align="center" styleCode="Botrule Lrule Rrule Toprule">Â </td>
                           <td align="center" styleCode="Botrule Lrule Rrule Toprule">159 (28.5)</td>
                           <td align="center" styleCode="Botrule Lrule Rrule Toprule">Â </td>
                           <td align="center" styleCode="Botrule Lrule Rrule Toprule">77 (40.7)</td>
                        </tr>
                     </tbody>
                  </table>
                  <paragraph>Subjects treated with Metronidazole Gel experienced a mean reduction of 9.4 inflammatory lesions in the Week-10 LOCF group, compared to a reduction of 5.6 for those treated with vehicle, or a difference in means of 3.8 lesions.</paragraph>
               </text>
               <effectiveTime value="20241031"/>
            </section>
         </component>
         <component>
            <section ID="ID_ae33109d-2bfd-4db8-8fce-cf5d0cd6c68b">
               <id root="093406bd-1492-4c9f-9eac-15b94c1076b2"/>
               <code code="34069-5" codeSystem="2.16.840.1.113883.6.1" displayName="HOW SUPPLIED SECTION"/>
               <title>16 HOW SUPPLIED/STORAGE AND HANDLING</title>
               <text>
                  <paragraph>
                     <content styleCode="underline">How Supplied</content>
                     <br/>Metronidazole Gel is clear, colorless to pale yellow in color, and supplied as follows:<br/> 55 gram pump â NDC 68308-663-55 <br/>60 gram tube â NDC 68308-663-60 <br/>
                     <br/>
                     <content styleCode="underline">Storage and Handling</content>
                     <br/>Store at controlled room temperature: 20Â° to 25Â°C (68Â° to 77Â°F), excursions permitted between 15Â° and 30Â°C (59Â° and 86Â°F).</paragraph>
               </text>
               <effectiveTime value="20241031"/>
            </section>
         </component>
         <component>
            <section ID="ID_8ee451b9-0744-4b8b-80b2-84f11300c174">
               <id root="dc178a2b-ab94-4865-823d-9fe763cc4d08"/>
               <code code="88436-1" codeSystem="2.16.840.1.113883.6.1" displayName="PATIENT COUNSELING INFORMATION"/>
               <title>17 PATIENT COUNSELING INFORMATION</title>
               <text>
                  <paragraph>Advise the patient to read the FDA-approved patient labeling (Patient Information).</paragraph>
                  <paragraph>
                     <content styleCode="underline">Administration Instructions</content>
                     <br/>Use as directed. Avoid contact with the eyes <content styleCode="italics">[see Warnings and Precautions (5.4)].</content>
                     <br/>Cleanse treated areas before the application of Metronidazole Gel<content styleCode="italics"> [see Dosage and Administration (2)] <br/>
                     </content>Advise patients to report any adverse reaction to their healthcare providers.<br/>
                     <br/>
                     <content styleCode="underline">Neurologic Disease</content>
                     <br/>Advise patients to immediately report any abnormal neurologic signs to their healthcare provider <content styleCode="italics">[see Warnings and Precautions (5.1)].</content>
                     <br/>
                     <br/>
                     <content styleCode="underline">Lactation</content>
                     <br/>Advise women not to breastfeed during treatment with Metronidazole Gel<content styleCode="italics"> [see Use in Specific Populations (8.2)].</content>
                  </paragraph>
                  <paragraph>
                     <content styleCode="bold">Rx Only<br/>
                     </content>US Patent No. 6,881,726 and 7,348,317<br/>Distributed by:<br/>
                     <content styleCode="bold">Mayne Pharma<br/>
                     </content>Raleigh, NC 27609Â <br/>P58252-0<br/>Product of Canada<br/>All trademarks are the property of their respective owners. <br/>
                     <br/>
                  </paragraph>
                  <paragraph/>
               </text>
               <effectiveTime value="20241031"/>
            </section>
         </component>
         <component>
            <section ID="ID_1a7b4c8a-7466-431d-832e-64134f095a2d">
               <id root="f3aaca3c-c891-4459-855d-c9902b045561"/>
               <code code="68498-5" codeSystem="2.16.840.1.113883.6.1" displayName="PATIENT MEDICATION INFORMATION SECTION"/>
               <title>PATIENT INFORMATION </title>
               <text>
                  <paragraph>
                     <content styleCode="bold">Metronidazole Gel<br/>
                     </content>
                  </paragraph>
                  <paragraph>
                     <content styleCode="bold">Important: <content styleCode="bold">Metronidazole GelÂ </content>is for use on the skin only (topical use). </content>Do not use Metronidazole Gel in your mouth, eyes, or vagina.</paragraph>
                  <paragraph>
                     <content styleCode="bold">What is <content styleCode="bold">Metronidazole Gel</content>?</content>
                     <br/>Metronidazole Gel is a prescription medicine used on the skin (topical) to treat pimples and bumps (inflammatory lesions) caused by a condition called rosacea. <br/>It is not known if Metronidazole Gel<content styleCode="bold">Â </content>is safe and effective in children.</paragraph>
                  <paragraph>
                     <content styleCode="bold">Do not use <content styleCode="bold">Metronidazole Gel</content>Â if </content>you are allergic to metronidazole or any of the ingredients in Metronidazole Gel. See the end of this leaflet for a complete list of ingredients in Metronidazole Gel.</paragraph>
                  <paragraph>
                     <content styleCode="bold">Before using <content styleCode="bold">Metronidazole Gel</content>, tell your healthcare provider about all your medical conditions, including if you:</content>
                  </paragraph>
                  <list listType="unordered">
                     <item>have tingling or numbness in your hands or feet</item>
                     <item>have or have had a blood disorder or disease</item>
                     <item>are pregnant or plan to become pregnant. It is not known if Metronidazole Gel will harm your unborn baby.</item>
                     <item>are breastfeeding or plan to breastfeed. It is not known if Metronidazole Gel passes into your breast milk. Do not breastfeed during treatment with Metronidazole Gel. Talk to your healthcare provider about the best way to feed your baby during treatment with Metronidazole Gel.</item>
                  </list>
                  <paragraph>
                     <content styleCode="bold">Tell your healthcare provider about all of the medicines you take</content>, including prescription and over-the-counter medicines, vitamins, and herbal supplements. <br/>Know the medicines you take. Keep a list of them to show your healthcare provider and pharmacist when you get a new medicine.</paragraph>
                  <paragraph>
                     <content styleCode="bold">How should I use <content styleCode="bold">Metronidazole Gel</content>?</content>
                  </paragraph>
                  <list listType="unordered">
                     <item>Use Metronidazole Gel exactly as your healthcare provider tells you to.</item>
                     <item>Cleanse the treated area before applying Metronidazole Gel.</item>
                     <item>Apply and rub in a thin film of Metronidazole Gel 1 time a day to the affected area(s).</item>
                     <item>You can apply cosmetics after applying Metronidazole Gel<content styleCode="bold">.Â </content>
                     </item>
                     <item>Avoid contact of Metronidazole Gel with your eyes.</item>
                  </list>
                  <paragraph>
                     <content styleCode="bold">What are the possible side effects of <content styleCode="bold">Metronidazole Gel</content>? <br/>
                        <content styleCode="bold">Metronidazole Gel</content>Â may cause serious side effects, including:</content>
                  </paragraph>
                  <list listType="unordered">
                     <item>
                        <content styleCode="bold">Peripheral neuropathy.</content> Tingling, burning, pain or numbness in the hands or feet (peripheral neuropathy) have happened in people treated with metronidazole used on the skin. Tell your healthcare provider if you experience tingling, burning, pain or numbness in your hands or feet during treatment with Metronidazole Gel.</item>
                     <item>
                        <content styleCode="bold">Skin reactions,</content> including allergic reactions. Tell your healthcare provider if you develop any skin reactions, including rash, itching, redness, swelling, or blisters during treatment with Metronidazole Gel.Â </item>
                     <item>
                        <content styleCode="bold">Eye irritation. </content>Tearing from eye irritation has happened in people treated with metronidazole used on the skin. Tell your healthcare provider if you experience tearing, redness or discomfort of the eyes during treatment with Metronidazole Gel.</item>
                  </list>
                  <paragraph>
                     <content styleCode="bold">The most common side effects of Metronidazole Gel include:</content>
                  </paragraph>
                  <list listType="unordered">
                     <item>sore throat and nasal congestion</item>
                     <item>upper respiratory tract infections</item>
                     <item>headache</item>
                  </list>
                  <paragraph>Tell your healthcare provider if you get any side effects during treatment with Metronidazole Gel.</paragraph>
                  <paragraph>These are not all of the possible side effects of Metronidazole Gel. <br/>Call your doctor for medical advice about side effects. You may report side effects to FDA at 1-800-FDA-1088. <br/>You may also report side effects to Mayne Pharma at 1-844-825-8500.</paragraph>
                  <paragraph>
                     <content styleCode="bold">How should I store <content styleCode="bold">Metronidazole Gel</content>?</content>
                  </paragraph>
                  <list listType="unordered">
                     <item>Store Metronidazole Gel at room temperature between 68Â°F to 77Â°F (20Â°C to 25Â°C). </item>
                  </list>
                  <paragraph>
                     <content styleCode="bold">Keep <content styleCode="bold">Metronidazole GelÂ </content>and all medicines out of the reach of children.</content>
                  </paragraph>
                  <paragraph>
                     <content styleCode="bold">General information about the safe and effective use of <content styleCode="bold">Metronidazole Gel</content>. <br/>
                     </content>Medicines are sometimes prescribed for purposes other than those listed in a Patient Information leaflet. Do not use Metronidazole Gel for a condition for which it was not prescribed. Do not give Metronidazole Gel to other people, even if they have the same symptoms that you have. It may harm them. You can ask your pharmacist or healthcare provider for information about Metronidazole Gel that is written for health professionals.</paragraph>
                  <paragraph>
                     <content styleCode="bold">What are the ingredients in <content styleCode="bold">Metronidazole Gel?</content>
                        <br/> Active ingredient:</content> metronidazole<br/>
                     <content styleCode="bold"> Inactive ingredients</content>: betadex, edetate disodium, hydroxyethyl cellulose, methylparaben, niacinamide, phenoxyethanol, propylene glycol, propylparaben and purified water<br/>
                     <br/>DistributedÂ by: <br/>
                     <content styleCode="bold">Mayne</content>
                     <content styleCode="bold">Â Pharma </content>
                     <br/>Raleigh, NC 27609<br/>P58252-0<br/>Product of Canada <br/>US Patent No. 6,881,726 and 7,348,317 <br/>
                     <br/>This Patient Information has been approved by the U.S. Food and Drug Administration. <br/>Revised 10/2024</paragraph>
               </text>
               <effectiveTime value="20241031"/>
            </section>
         </component>
         <component>
            <section ID="ID_1eb6d9bd-1221-4bb4-af56-c657a2a58df3">
               <id root="f990fba4-658b-4ebd-8b20-c2aa96eaffe3"/>
               <code code="51945-4" codeSystem="2.16.840.1.113883.6.1" displayName="PACKAGE LABEL.PRINCIPAL DISPLAY PANEL"/>
               <title>PACKAGE LABEL - 55g pump</title>
               <text>
                  <renderMultiMedia referencedObject="MM85743"/>
                  <paragraph>
                     <content styleCode="bold">NDCÂ 68308-<content styleCode="bold">663</content>-55<br/>
                        <br/>Metronidazole Gel 1%<br/>
                        <br/>
                     </content>
                     <content styleCode="bold">Pump<br/>
                     </content>
                     <br/>For topical use only<br/>
                     <br/>
                     <br/>Rx Only<br/>
                     <br/>NET WT. 55g<br/>maynepharma<br/>
                     <br/>
                     <br/>
                     <content styleCode="bold">For topical use only. <br/>Not for oral, ophthalmic or intravaginal use.<br/>
                     </content>
                     <br/>Store at controlled room temperature, 68Â° to 77Â°F (20Â° - 25Â°C), excursions permitted between 59Â° to 86Â°F (15Â° - 30Â°C).<br/>Keep out of reach of children.<br/>
                     <br/>
                     <content styleCode="bold">Usual dosage:</content>Â Apply a thin film once a day to the affected areas.Â  See package insert for complete prescribing instructions.<br/>
                     <br/>
                     <br/>
                     <content styleCode="bold">Each gram contains: </content>10 mg (1%) metronidazole as active ingredient in a gel base consisting of betadex, edetate disodium, hydroxyethl cellulose, methylparaben, niacinamide, phenoxyethanol, propylene glycol, propylparben, and purified water.<br/>
                     <br/>
                     <br/>
                     <br/>
                  </paragraph>
                  <paragraph>Distributed by:<br/>
                     <content styleCode="bold">Mayne Pharma</content>
                     <br/>Raleigh, NC 27609<br/>Product of Canada.<br/>
                     <br/>P57418-0</paragraph>
               </text>
               <effectiveTime value="20241031"/>
            </section>
         </component>
         <component>
            <section ID="ID_90fadf61-f2f6-4804-b515-a63d11e8bd48">
               <id root="4ee46dc8-1791-4ffa-85d9-4d6da36d9c3f"/>
               <code code="51945-4" codeSystem="2.16.840.1.113883.6.1" displayName="PACKAGE LABEL.PRINCIPAL DISPLAY PANEL"/>
               <title>PACKAGE LABEL - 60g Tube</title>
               <text>
                  <paragraph/>
                  <renderMultiMedia referencedObject="MM88226"/>
                  <paragraph>NDCÂ 68308<content styleCode="bold">-<content styleCode="bold">663</content>-</content>60<br/>
                     <content styleCode="bold">Metronidazole Gel</content>
                     <br/>
                     <content styleCode="bold"> 1%Â </content>
                     <br/>
                     <content styleCode="bold">For Topical Use Only</content>
                     <br/>
                     <br/>Rx Only<br/>Net Wt. 60 g<br/>
                     <br/>maynepharma<br/>
                     <br/>Product of Canada<br/>Distributed by:<br/>
                     <content styleCode="bold">MaynePharma</content>
                     <br/>Raleigh, NC 27609<br/>
                     <br/>P58251-0<br/>
                     <br/>
                     <br/>
                     <content styleCode="bold">FOR TOPICAL USE ONLY. NOT FOR ORAL, OPHTHALMIC OR INTRAVAGINAL USE.<br/>STORE AT CONTROLLED ROOM TEMPERATURE 68Âº TO 77ÂºF(20Âº - 25Âº C)<br/>EXCURSIONS PERMITTED BETWEEN 59Âº AND 86ÂºF (15Âº - 30ÂºC)</content>
                     <br/>
                     <br/>
                     <content styleCode="bold">Usual dosage:</content>Â Apply a thin film once a day to the affected areas.Â  <br/>See package insert for complete prescribing instructions.<br/>
                     <br/>
                     <content styleCode="bold">Each gram contains: Active:Â </content>10 mg (1%) metronidazole as active ingredient in a gel base consisting of betadex, edetate disodium, hydroxyethl cellulose, methylparaben, niacinamide, phenoxyethanol, propylene glycol, propylparben, and purified water.<br/>
                     <br/>See crimp of tube for lot number and expiration date.<br/>
                     <br/>
                     <br/>
                  </paragraph>
               </text>
               <effectiveTime value="20241031"/>
            </section>
         </component>
      </structuredBody>
   </component>
</document>